Обзорная статья

Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19

Saman YasaminehDepartment of Medical Microbiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, IranHesam Ghafouri KalajahiDepartment of Biotechnology, Institute of Science, Uskudar University, Istanbul, TurkeyPooneh YasaminehYoung Researchers and Elite Club, Tabriz Branch, Islamic Azad University, Tabriz, IranOmid GholizadehDepartment of Bacteriology and Virology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, IranHamed Rahmani YoushanloueiDepartment of Internal Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, IranSaeed Karimi MatloubStudents Research Committee, Qom University of Medical Sciences, Qom, IranMasoud MozafariCardiovascular Pharmacology Research Lab, Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IranElham JokarDepartment of Medical Chemistry, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IranYalda YazdaniImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. [email protected]Mehdi DadashpourCancer Research Center, Semnan University of Medical Sciences, Semnan, Iran. [email protected]

2022en

ABI

Аннотация

The SARS-COV-2 virus has infected the world at a very high rate by causing COVID-19 disease. Nearly 507 million individuals have been infected with this virus, with approximately 1.2% of these patients being dead, indicating that this virus has been out of control in many countries. While researchers are investigating how to develop efficient drugs and vaccines versus the COVID-19 pandemic, new superseded treatments have the potential to reduce mortality. The recent application of mesenchymal stem cells (MSCs) in a subgroup of COVID-19 patients with acute respiratory distress has created potential benefits as supportive therapy for this viral contagion in patients with acute conditions and aged patients with severe pneumonia. Consequently, within this overview, we discuss the role and therapeutic potential of MSCs and the challenges ahead in using them to treat viral infections, with highlighting on COVID-19 infection.

Перевод пока недоступен

Идентификаторы

DOI: 10.1186/s13287-022-02944-7

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar